A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy.
Phase of Trial: Phase IV
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Efavirenz (Primary) ; Maraviroc (Primary) ; Raltegravir (Primary) ; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms CCRC
- 10 Jun 2017 Biomarkers information updated
- 16 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jan 2013 Planned End Date changed from 1 Apr 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.